Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

Bristol Myers Squibb has faced patent cliffs in recent years and will face more in the next few years. The company's portfolio of newer drugs, along with its deep pipeline, can help it overcome this headwind.